Interferon alfa-2b

Generic Name: Interferon alfa-2b

Brand Names: Intron A

Drug Type: Biotech

CAS Number: 98530-12-2

Unique Ingredient Identifier: 43K1W2T1M6

Background: Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.

Indication: For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.

Associated Conditions: Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, Condylomata Acuminata (External), Follicular Non-Hodgkin's Lymphoma, Hairy Cell Leukemia (HCL), Kaposi's Sarcoma, Malignant Melanoma

Clinical Trials

First In Human Study of CX-801 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor, Adult

Interventions: Drug: CX-801
Drug: pembrolizumab

First Posted Date: 2024-06-17

Last Posted Date: 2024-08-12

Lead Sponsor: CytomX Therapeutics

Target Recruit Count: 121

Registration Number: NCT06462794

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL

Not Applicable

Recruiting

Conditions: Tumour

Interventions: Drug: interferon α-2b

First Posted Date: 2024-06-10

Last Posted Date: 2024-06-10

Lead Sponsor: Zhejiang Provincial People's Hospital

Target Recruit Count: 15

Registration Number: NCT06450145

Locations: 🇨🇳
First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2

Active, not recruiting

Conditions: HLA-A2 Positive Cells Present
Refractory Melanoma

Interventions: Biological: Alpha-type-1 Polarized Dendritic Cells
Drug: Celecoxib
Drug: PD-1 Ligand Inhibitor
Drug: PD1 Inhibitor
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod

First Posted Date: 2019-09-18

Last Posted Date: 2025-05-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 1

Registration Number: NCT04093323

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Phase 2

Recruiting

Conditions: Prostate Adenocarcinoma
Stage II Prostate Cancer AJCC v8
Stage IIA Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Stage I Prostate Cancer AJCC v8
Stage IIC Prostate Cancer AJCC v8
Stage IIB Prostate Cancer AJCC v8
Stage III Prostate Cancer AJCC v8
Stage IIIB Prostate Cancer AJCC v8

Interventions: Drug: EC Aspirin
Procedure: Radical Prostatectomy
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod

First Posted Date: 2019-04-02

Last Posted Date: 2025-04-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT03899987

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3

Active, not recruiting

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Non-Cutaneous Melanoma
Recurrent Cutaneous Melanoma
Recurrent Mucosal Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Metastatic Cutaneous Melanoma
Metastatic Mucosal Melanoma
Recurrent Non-Cutaneous Melanoma
Non-Cutaneous Melanoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Ipilimumab
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment
Biological: Recombinant Interferon Alfa-2b

First Posted Date: 2015-07-23

Last Posted Date: 2025-04-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1301

Registration Number: NCT02506153

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸
Virginia G Piper Cancer Care-Del Camino, Scottsdale, Arizona, United States

and more 575 locations

Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients

Phase 4

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Entecavir
Drug: Interferon alfa-2b
Drug: Interleukin 2
Drug: Hepatitis B Vaccine

First Posted Date: 2015-02-10

Last Posted Date: 2018-05-09

Lead Sponsor: Tongji Hospital

Target Recruit Count: 94

Registration Number: NCT02360592

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
BeiJing YouAn Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
First Hospital, Beijing University, Beijing, Beijing, China

and more 9 locations

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Phase 4

Terminated

Conditions: Lymphoma, T-Cell, Cutaneous
Mycosis Fungoides

Interventions: Drug: Methotrexate
Drug: Interferon Alfa-2b

First Posted Date: 2014-12-23

Last Posted Date: 2022-01-13

Lead Sponsor: Polish Lymphoma Research Group

Target Recruit Count: 100

Registration Number: NCT02323659

Locations: 🇵🇱
Centrum Onkologii im. prof. F. Łukaszczyka, Bydgoszcz, Poland

Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia

Phase 4

Completed

Conditions: Conjunctival Intraepithelial Neoplasia
Corneal Intraepithelial Neoplasia

Interventions: Drug: Mitomycin C
Drug: Interferon Alfa-2b

First Posted Date: 2014-07-24

Last Posted Date: 2017-08-08

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 18

Registration Number: NCT02199327

Locations: 🇲🇽
IMSS Centro Médico de Occidente, Guadalajara, Jalisco, Mexico

Interferon α for the Therapy of Minimal Residual Disease

Not Applicable

Conditions: Leukemia

Interventions: Drug: Interferon Alfa-2b

First Posted Date: 2014-07-09

Last Posted Date: 2018-06-07

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 81

Registration Number: NCT02185261

Locations: 🇨🇳
Peking University Institute of Hematology,Beijing, Beijing, Beijing, China

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Cancers

Interventions: Drug: Atezolizumab
Drug: Ipilimumab
Drug: Interferon alfa-2b
Drug: PEG-interferon alfa-2a
Drug: Bevacizumab
Drug: Obinutuzumab

First Posted Date: 2014-06-25

Last Posted Date: 2020-05-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 158

Registration Number: NCT02174172

Locations: 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy